Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas

Modern Pathology

Volumn 17, Issue 7, 2004, Pages 756-764

  Miller, Dylan V ^a   Leontovich, Alexey A ^a   Lingle, Wilma L ^a   Suman, Vera J ^b   Mertens, Maureen L ^c   Lillie, James ^c   Ingalls, Kimberly A ^c   Perez, Edith A ^d   Ingle, James N ^b   Couch, Fergus J ^a   Visscher, Daniel W ^a,b  

^a Department of Anatomic Pathology ^*

^b MAYO CLINIC   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Breast neoplasms; Carcinoma, infiltrating duct; cDNA microarray; Gene expression profiling; Nottingham Prognostic Index

Indexed keywords

COMPLEMENTARY DNA; RNA;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA MICROARRAY; EXPRESSED SEQUENCE TAG; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOSS; GENETIC GAIN; GENETIC INSTABILITY; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MALE; MEASUREMENT; METASTASIS POTENTIAL; NOTTINGHAM PROGNOSTIC INDEX; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; DNA-BINDING PROTEINS; EXPRESSED SEQUENCE TAGS; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SMAD4 PROTEIN; TRANS-ACTIVATORS;

EID: 3042526149     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800114     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
3. Isaccs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol 2001;28:53-67.
4. Anderson TJ, Alexander FE, Lamb J, et al. Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 2000;83:487-492.
5. Ochs MF, Godwin AK. Microarrays in cancer: research and applications. Biotechniques 2003;34:S4-S15.
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
7. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
8. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-548.
9. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
10. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
11. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-5984.
12. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001;98:11462-11467.
13. van't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer (Letter). Breast Cancer Res 2002;5:57-58.
14. Ahr A, Holtrich U, Solbach C, et al. Molecular classification of breast cancer by gene expression profiling. J Pathol 2001;195:312.
15. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-219.
16. Anderson TJ. Breast cancer prognostication in the 21st century and the Nottingham prognostic index (Editorial). J Clin Pathol 2002;55:86-87.
17. Cserni G. The effect of sentinel lymph node biopsy on the Nottingham Prognostic Index in breast cancer patients. J R Coll Surg Edinburg 2001;46:208-212.
18. Balslev I, Axelsson CK, Zedeler K, et al. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994;32:281-290.
19. D'Eredita G, Giardina C, Martellotta M, et al. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-596.
20. Sundquist M, Thorstenson S, Brudin L, et al. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999;53:1-8.
21. Robertson JF, Dixon AR, Nicholson RI, et al. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 1992;22:221-227.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1991;19:403-410.
23. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-1549.
24. Nourse CR, Mattei MG, Gunning P, et al. Cloning of a third member of the D52 gene family indicates alternative coding sequence usage in D52-like transcripts. Biochim Biophys Acta 1998;1443:155-168.
25. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002;21:483-492.
26. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
27. Okamura S, Arakawa H, Tanaka T, et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001;8:85-94.
28. Kovanen PE, Rosenwald A, Fu J, et al. Analysis of gamma c-Family Cytokine Target Genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J Biol Chem 2003;278:5205-5213.
29. Blokzijl A, ten Dijke P, Ibanez CF. Physical and functional interaction between GATA-3 and Smad3 allows TGF-beta regulation of GATA target genes. Curr Biol 2002;12:35-45.
30. Maki RG, Old LJ, Srivastava PK. Human homologue of murine tumor rejection antigen gp96: 5′-regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci USA 1990;87:5658-5662.
31. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-193.
32. McCarthy DM, Hruban RH, Argani P, et al. Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of vater: analysis of 140 cases. Mod Pathol 2003;16:272-278.
33. Bertucci F, Houlgatte R, Benziane A, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes GATA-3 is expressed in association with estrogen receptor in breast cancer. Hum Mol Genet 2099;9:2981-2991.
34. Hoch RV, Thompson DA, Baker RJ, et al. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999;84:122-128.
35. Forozan F, Mahlamaki EH, Monni O, et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000;60:4519-4525.
36. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diag Mol Patho 2000;9:14-19.
37. Climent J, Martinez-Climent JA, Blesa D, et al. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin Cancer Res 2002;8:3863-3869.
38. Gaki V, Tsopanomichalou M, Sourvinos G, et al. Allelic loss in chromosomal region 1q21-23 in breast cancer is associated with peritumoral angiolymphatic invasion and extensive intraductal component. Eur J Surg Oncol 2000;26:455-460.
39. Bieche I, Champeme MH, Lidereau R. Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1995;1:123-127.
40. Minobe K, Onda M, Iida A, et al. Allelic loss on chromosome 9q is associated with lymph node metastasis of primary breast cancer. Jpn J Cancer Res 1998;89:916-922.
41. Hislop RG, Pratt N, Stocks SC, et al. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 2002;89:1581-1586.
42. Pandis N, Jin Y, Gorunova L, et al. Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer 1995;12:173-185.